TIFU: A Non-Interventional, Descriptive Cohort Study to Describe the Use of Ticagrelor in Patients With Acute Coronary Syndrome (TIFU: Ticagrelor in Fuwai Hospital)
Trial Snapshot
- Phase
- Not Applicable
- Sponsor
- Enrollment
- 1,200
- Locations
- 1
- Primary Endpoint
- Number of participants with switching between clopidogrel and ticagrelor
Study Overview
Brief Summary
This is a single-arm non-interventional cohort study. This study is to describe the contemporary use of ticagrelor in a "real-world" setting, to reflect its acceptance and patients' compliance, and to observe its one-year safety in patients with acute coronary syndrome in Fuwai Hospital.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Established diagnosis of acute coronary syndrome
- •The use of ticagrelor in hospital
- •agree to join this clinical trial and sign informed consent
Exclusion Criteria
- •Life-expectancy <1 year
- •Dialysis required
Outcomes
Primary Outcomes
Number of participants with switching between clopidogrel and ticagrelor
Time Frame: 12 months
Number of participants with switching between clopidogrel and ticagrelor without a reloading dose
Time Frame: 12 months
Number of Participants with discontinuation of P2Y12 receptor antagonist
Time Frame: 12 months
Number of Participants with ticagrelor combined with other anticoagulants
Time Frame: 12 months
Secondary Outcomes
- Cardiovascular Mortality, Myocardial Infarction(MI), Ischemic Stoke(12 months)
- Number of bleeding event will be recorded (defined in accordance with PLATO definition)(12 months)
Investigators
Hongbing Yan
The deputy director of Center of Coronary Heart Disease and Center of Chest Pain
Chinese Academy of Medical Sciences, Fuwai Hospital